Suvremeno liječenje arterijske hipertenzije fiksnom kombinacijom telmisartan-hidroklorotiazid. (Croatian)

Contemporary treatment of hypertension by fixed-dose combination of telmisartan-hydrochlorothiazide. (English)

Fixed-dose combination of telmisartan and hydrochlorothiazide is another contemporary option of effective treatment of hypertension. It is a combination of an angiotensin II receptor blocker, telmisartan and thiazide diuretic, hydrochlorothiazide. Telmisartan reduces cardiovascular risk not only by reducing blood pressure (BP), but also by reducing other metabolic parameters that have a positive effect on cardiovascular diseases, especially selective modulation of PPAR-γ. Hydrochlorothiazide has an effect on the renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of sodium and chloride in approximately equal amounts. Different combinations of telmisartan and hydrochlorothiazide (40/12,5; 80/12,5 and 80/25 mg) are used in the treatment of hypertension in adults whose BP is not well controlled by using telmisartan alone or in patients who have been previously stabilized by telmisartan and hydrochlo-rothiazide administered separately. [ABSTRACT FROM AUTHOR]

Fiksna kombinacija telmisartana i hidrokloro-tiazida predstavlja još jednu suvremenu mogućnost učinkovitog liječenja arterijske hipertenzije. To je kombinacija antagonista receptora angiotenzina II, telmisartana i tijazidskog diuretika, hidroklorotiazida. Telmisartan smanjuje kardiovaskularni rizik ne samo smanjenjem vrijednosti arterijskog tlaka (AT), nego i smanjenjem drugih metaboličkih parametara koji imaju pozitivan učinak na srčanožilne bolesti, primjerice selektivna modulacija PPAR-γ. Hidroklorotiazid ima učinak na renalne tubularne mehanizme reapsorpcije elektrolita, izravno povećavajući ekskreciju natrija i klorida u približno jednakim količinama. Različite kombinacije telmisartana i hidroklo-rotiazida (40/12,5; 80/12,5 i 80/25 mg) se primjenjuju u liječenju arterijske hipertenzije odraslih osoba čiji AT nije dobro kontroliran uz primjenu samog telmisartana ili kod bolesnika koji su prethodno stabilizirani telmisartanom i hidroklorotiazidom davanim zasebno. [ABSTRACT FROM AUTHOR]

Copyright of Cardiologia Croatica is the property of Croatian Cardiac Society and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)